Mac Lochlainn, DJ;
McKechnie, DGJ;
Mehta, AB;
Hughes, DA;
(2018)
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Molecular Genetics and Metabolism
, 123
(2)
pp. 154-158.
10.1016/j.ymgme.2017.10.001.
Preview |
Text
McKechnie_MGM_2017_361_Revision 1_V0 (3).pdf - Accepted Version Download (202kB) | Preview |
Abstract
Fabry disease is a rare X-linked lysosomal storage disorder in which there is deficiency of alpha galactosidase A. Enzyme replacement therapy (ERT) is commercially available and has been demonstrated to improve cardiac and renal outcomes. Predictive scores, such as the Fabry International Prognostic Index (FIPI), have been developed to stratify disease severity; however, these have not been validated to predict outcomes in patients receiving ERT. We show that the FIPI score at baseline can predict outcomes in a group of patients on long-term ERT.
Archive Staff Only
 |
View Item |
